* = Guardant360 Liquid CDx is under review with Notified Body / EMA
1. Guardant360 Liquid CDx Assay Specifications. May 2026. Guardant Health, Inc. Redwood City. CA; 2. Mosele, Annals of Oncology 2024: 3. Gross A, Zhao J, Quinn K, et al. Landscape of epigenomic tumor fraction in a large pan-cancer cfDNA cohort. Abstract 5936. Cancer Res. 2025;85(8 suppl 1):5936. doi:10.1158/1538-7445.AM2025-5936; 4. Marcus, FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors, Clin Cancer Res. 2021; 5. Marabelle, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, JCO 2020
Home Oncology Portfolio Partnerships European Policy
Covered guideline – recommended biomarkers
for common cancer types:
*1,2
Tumor Fraction: Measure tumor DNA levels using thousands of differentially methylated regions.1,3
Tumor Mutational Burden (TMB) and MSI (Micro
Satellites Instability):
Identify TMB and MSI status
to inform the use of Immunotherapy.1,4,5